NCT06894875 Effects of Lentil Protein Hydrolysate on Blood Pressure Control, Vascular Function and Exercise Performance
| NCT ID | NCT06894875 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Nuritas Ltd |
| Condition | Exercise |
| Study Type | INTERVENTIONAL |
| Enrollment | 48 participants |
| Start Date | 2025-06-24 |
| Primary Completion | 2025-12-24 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 48 participants in total. It began in 2025-06-24 with a primary completion date of 2025-12-24.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Examining the safety and tolerability of Lentil Protein Hydrolysate in healthy males and females whilst exploring the effects of a dose range on blood pressure control and vascular function and exercise performance
Eligibility Criteria
Inclusion Criteria: * Willing to provide written and dated informed consent to participate in the study. * Willing and able to comply with the protocol. * Are not on any medication, or supplements which would impact the trial in the opinions of the investigator or Sponsor. * Male or female between 18 and 45 years of age (18.5 kg/m2 ≥ BMI \< 30 kg/m2). * Comply with ACSM guidelines for physical activity. * Have not participated in a clinical trial within the past month and agree to not participate in another clinical trial during the study period. * Agree to not significantly alter diet or exercise routine during the trial period. * Willing to wear a wearable device continuously for the duration of the study Exclusion Criteria: * Subjects having a known allergy or hypersensitivity to any of the ingredients in the investigational products. * Subjects with a history of alcohol and/or other drug abuse in the past year. * Has performed strenuous exercise (rating of perceived exertion ≥ 13) ≤ 48 hours before laboratory visit (Borg, 1982). * Consuming \>14 alcoholic drinks per week or \> 2 drinks/day in the 48 hours preceding a clinic visit. * Active smokers, nicotine use or vaping * Subjects suffering from a sleep disorder and/or who have a known history of (or was being treated for) clinical depression, eating disorder(s) or any other psychiatric condition(s) that might put the subject at risk and/or confounded the results of the study. * Subjects with a history of being diagnosed with phenylketonuria or another disease affecting amino acid metabolism (i.e., maple syrup urine disease, etc.). * Subjects with an elevated resting heart rate (\>100 bpm) or blood pressure (systolic BP \>140 mmHg or diastolic BP \>90 mmHg). * Pregnant or lactating women * Presentation of orthostatic hypotension during the screening and familiarisation study visit * Any condition which in the opinion of the investigator makes the participant unsuitable for inclusion.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06894875 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 45 Years, studying Exercise. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06894875 currently recruiting?
Yes, NCT06894875 is actively recruiting participants. Contact the research team at mohan.niamh@nuritas.com for enrollment information.
Where is the NCT06894875 trial being conducted?
This trial is being conducted at Melbourne, Australia.
Who is sponsoring the NCT06894875 clinical trial?
NCT06894875 is sponsored by Nuritas Ltd. The trial plans to enroll 48 participants.